全身磁共振成像用于高危前列腺癌患者分期
研究前瞻性纳入92例新诊断高危前列腺癌患者,比较全身磁共振成像(WBMRI)与常规影像(CT和骨显像)的诊断效能。WBMRI检测淋巴结转移的敏感度高于CT(0.60 vs 0.20,p=0.031),两者特异度和准确度相同;检测骨转移的敏感度、特异度和准确度与CT和骨显像相近。
要点
- WBMRI检测淋巴结转移的敏感度为0.60,高于CT的0.20(p=0.031)。
- WBMRI与CT检测淋巴结转移的特异度和准确度均为0.84和0.80。
- WBMRI检测骨转移的敏感度0.25、特异度0.94、准确度0.88,与CT和骨显像相近。
核心结论
- 对于高危前列腺癌患者分期,WBMRI检测淋巴结转移优于CT,检测骨转移与CT和骨显像相当。
研究设计与样本
- 前瞻性纳入新诊断高危前列腺癌患者(前列腺特异性抗原≥20 ng/ml和/或Grade Group≥4),共92例。
- 患者在评估后30天内接受骨显像、腹部和盆腔CT以及WBMRI检查。
- 主要终点为WBMRI与常规影像检测淋巴结和骨转移的诊断效能,参考标准为组织病理学或6个月随访时所有可用临床信息。
主要发现
- 92例患者中,15例(16.3%)发现淋巴结转移,8例(8.7%)发现骨转移。
- WBMRI检测淋巴结转移的敏感度0.60(95%CI 0.32-0.84)、特异度0.84(95%CI 0.74-0.92)、准确度0.80(95%CI 0.71-0.88);CT分别为0.20(95%CI 0.04-0.48)、0.92(95%CI 0.84-0.97)、0.80(95%CI 0.71-0.88)。
- WBMRI检测骨转移的敏感度0.25(95%CI 0.03-0.65)、特异度0.94(95%CI 0.87-0.98)、准确度0.88(95%CI 0.80-0.94);CT和骨显像分别为0.12(95%CI 0-0.53)、0.94(95%CI 0.87-0.98)、0.87(95%CI 0.78-0.93)。
- 评估淋巴结转移时,WBMRI敏感度高于CT(p=0.031),曲线下面积(AUC)也高于CT(0.72 vs 0.56,p=0.019)。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文指出需进一步研究评估WBMRI的成本效益以及PSMA PET与WBMRI联合应用的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staging patients with high-risk prostate cancer (HRPCa) with conventional imaging of computed tomography (CT) and bone scintigraphy (BS) is suboptimal. Therefore, we aimed to compare the accuracy of whole-body magnetic resonance imaging (WBMRI) with conventional imaging to stage patients with HRPCa. METHODS: We prospectively enrolled patients with newly diagnosed HRPCa (prostate-specific antigen ≥20 ng/ml and/or Grade Group ≥4). Patients underwent BS, CT of the abdomen and pelvis, and WBMRI within 30 days of evaluation. The primary endpoint was the diagnostic performances of detecting metastatic disease to the lymph nodes and bone for WBMRI and conventional imaging. The reference standard was defined by histopathology or by all available clinical information at 6 months of follow-up. To compare diagnostic tests, Exact McNemar's test and area under the curve (AUC) of the receiver operating characteristics curves were utilized. RESULTS: Among 92 patients enrolled, 15 (16.3%) and 8 (8.7%) patients were found to have lymphatic and bone metastases, respectively. The sensitivity, specificity, and accuracy of WBMRI in detecting lymphatic metastases were 0.60 (95% confidence interval 0.32-0.84), 0.84 (0.74-0.92), and 0.80 (0.71-0.88), respectively, while CT were 0.20 (0.04-0.48), 0.92 (0.84-0.97), and 0.80 (0.71-0.88). The sensitivity, specificity, and accuracy of WBMRI to detect bone metastases were 0.25 (0.03-0.65), 0.94 (0.87-0.98), and 0.88 (0.80-0.94), respectively, while CT and BS were 0.12 (0-0.53), 0.94 (0.87-0.98), and 0.87 (0.78-0.93). For evaluating lymphatic metastases, WBMRI demonstrated a higher sensitivity (p = 0.031) and discrimination compared to CT (0.72 versus 0.56, p = 0.019). CONCLUSIONS: For staging patients with HRPCa, WBMRI outperforms CT in the detection of lymphatic metastases and performs as well as CT and BS in the detection of bone metastases. Further studies are needed to assess the cost effectiveness of WBMRI and the utility of combined PSMA PET and WBMRI.
引用
- Fang AM, Chapin BF, Shi CW, et al. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 39289537. doi:10.1038/s41391-024-00893-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。